Why do transformative cancer therapies need innovative biomarkers? Because complex tumor biology often limits success. AI can deliver quantifiable, precise, and scalable insights from tissue that improve trial outcomes.
Our comprehensive suite of Lunit SCOPE solutions applies digital pathology AI to address key challenges in translational research, clinical trial efficiency, and biomarker discovery and development.
Harness TME insights with AI-powered immune phenotyping and feature analysis to enable biomarker discovery with a single H&E analysis.
For Research Use Only. Not for use in diagnostic procedures or decisions
Advance your IHC biomarker strategy with AI pathology analysis that accelerates development, enriches clinical trials, and boosts efficiency.
For Research Use Only. Not for use in diagnostic procedures or decisions
Rapidly extract AI-powered prediction of tumor characteristics including mutation and target protein expression from H&E slides for fast, scalable, and cost-effective pre-screening and co-mutation discovery.
For Research Use Only. Not for use in diagnostic procedures or decisions
Stay informed with the latest research, product updates, and global partnerships driving innovation in AI-powered precision oncology.
